21% PRMB CRASH: Hagens Berman Scrutinizing Primo Brands (PRMB) Over Allegedly Concealed Merger Failure, CEO Replacement, and “Self-Inflicted” Disruptions

Partner Reed Kathrein Investigating Management's Claims of “Flawless” Merger Against Alleged Operational Collapse in Direct Delivery Business National shareholder rights law firmHagens Berman is alerting investors in Primo Brands Corporation (NYSE: PRMB) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 12, 2026. […]

CBL International Limited Achieves EcoVadis Silver Medal, Ranking Among Top 15% Globally for Sustainability Performance

CBL International Limited (NASDAQ: BANL) (the "Company" or "CBL"), the listing vehicle of the Banle Group ("Banle" or "the Group") is proud to announce it has been awarded the prestigious EcoVadis Silver Medal, placing the company among the top 15% of organizations globally assessed for sustainability performance. The EcoVadis Silver Medal recognizes CBL's robust sustainability

Silver One Expands Exploration for High-Grade Silver at Phoenix Silver

Vancouver, British Columbia–(Newsfile Corp. – December 16, 2025) – Silver One Resources Inc. (TSXV: SVE) (OTCQX: SLVRF) (FSE: BRK1) (“Silver One” or the “Company”) is pleased to announce that it is commencing a detailed drone-borne magnetometry survey and a ground-penetrating radar (“GPR”) survey at its 100%-owned Phoenix Silver Project in Arizona. The surveys will cover

54% STRIDE (LRN) CRASH: Hagens Berman Scrutinizing Stride (LRN) Over Alleged “Ghost Students” Fraud and Concealed Tech Failure

Partner Reed Kathrein Investigating Alleged Fraudulent Enrollment Metrics and the Direct Causation Linking Operational Failure to Massive Investor Losses National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Stride, Inc. (NYSE: LRN) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action

Lexington Partners Expands Global Presence with Opening of Abu Dhabi Office

Doug Bourne Appointed to Lead Office; Thomas Dunn Relocates from London – Lexington Partners (“Lexington”), one of the world's largest and most experienced managers of secondary private equity and co-investment funds, today announced the opening of its new office in Abu Dhabi, expanding the firm's global footprint to nine offices across four continents. The establishment

MARRIAGETOXIN Ties the Knot on New Visuals, First Trailer and Cast Announcements

Today, the MARRIAGETOXIN Project announced the release of an all-new main visual, first trailer, and additional main staff for the highly anticipated hitman x marriage swindler, battle-action series, MARRIAGETOXIN. The anime adaptation from BONES Film, known for My Hero Academia and Gachiakuta, welcomes Anna Nagase, Mariya Ise, Asaki Yuikawa, Soma Saito, Hinano Shirahama, and Simba

U.S. News Reveals the 2026 Best Vacations Rankings

World's Best Places to Visit and Best Places to Visit in the USAboth have a new No. 1. U.S. News & World Report, publisher of Best Hotels, Best Cruise LinesandBest Travel Rewards Programs, today released its annual rankings of the Best Vacations. The 2026 rankings highlight 18 regional destination categories to help travelers find the

Polyplastics Expands LAPEROS(R) LCP Range to Meet Demands of Electronics Industry

Polyplastics Co., Ltd., a global leader in engineering thermoplastics, has expanded its LAPEROS(R) liquid crystal polymer (LCP) product line with the launch of the new LH and TF series materials, which meet the electronics market's growing demand for higher performance and miniaturization. These new LCP series grades will accelerate expansion into a broader range of

Breaking the “Untreatable”: Biostar Pharma’s UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases

Biostar Pharma, Inc., the U.S. wholly-owned subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. (Stock Code:2563.HK),today announced that the first patient has been dosed for one of its key oversea clinical studies: the U.S. pivotal clinical study (NCT06764940) of Utidelone Injection(UTD1) combined with capecitabine for the treatment of HER2-negative breast cancer brain metastases (BCBM). The study

Scroll to Top